[1] DS Ross, HB Burch, DS Cooper, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and other causes of Thyrotoxicosis. Thyroid, 2016; 26, 1343-421. doi:  10.1089/thy.2016.0229
[2] SY Cui, L Jiao, J Tan, et al. Estimating radiation absorbed dose of individuals nearby 131I-treated hyperthyroid patients. Health Phys, 2014; 106, 365-9. doi:  10.1097/HP.0b013e3182a1c8d5
[3] Demir M, Kabasakal L, Onsel C. Evaluation of external radiation exposure rate from radioiodine-treated hyperthyroid patients and radiation safety considerations. Nucl Med Commun, 1996; 17, 692-5. doi:  10.1097/00006231-199608000-00008
[4] Sartor O, Hoskin P, Bruland OS. Targeted radio-nuclide therapy of skeletal metastases. Cancer Treat. Rev, 2013; 39, 18-26. doi:  10.1016/j.ctrv.2012.03.006
[5] MJ O'Doherty, AG Kettele, CNEustance, et al. Radiation dose rates from adult patients receiving 131I therapy for thyrotoxicosis. Nucl Med Commun, 1993; 14, 160-8. doi:  10.1097/00006231-199303000-00003
[6] JA Siegel, CS Marcus, RB Sparks. Calculating the absorbed dose from radioactive patients:the line-source versus point-source model. J Nucl Med, 2002; 43, 1241-4. http://europepmc.org/abstract/MED/12215565
[7] International Commissioin on Radiological Protection. ICRP Publication 53. Radiation Dose to Patients from Radiopharmaceuticals. Pergamom Press: Oxford, UK, 1988.
[8] SR Thomas, HR Maxon, KM Fritz, et al. A comparison of methods for assessing patient body burden following 131I therapy for thyroid cancer. Radiology, 1980; 137, 839-42. doi:  10.1148/radiology.137.3.7444070
[9] JA Siegel, CS Marcus, MG Stabin. Licensee over-reliance on conservatisms in NRC guidance regarding the release of patients treated with 131I. Health Phys, 2007; 93, 667-77. doi:  10.1097/01.HP.0000270300.34270.44
[10] AP Jacobson, PA Plato, D Toeroek. Contamination of the home environment by patients treated with iodine-131:initial results. Am J Public Health, 1978; 68, 225-30. doi:  10.2105/AJPH.68.3.225